Friday, 16 October 2026European Markets

GRAINES VOLTZ Stock Is 13% Down So Far On Tuesday

Loading stream...

(vianews) - shares of graines voltz (cac 40: grvo.pa) dropped by a staggering 13.03% to €53.40 at 11:57 est on tuesday, following the last session's upward trend. cac 40 is jumping 0.32% to €7,100.85, following the last session's upward trend. this seems, at the moment, a somewhat bullish trend trading session today.

about graines voltz

graines voltz s.a. engages in the distribution of seeds, vegetable plants, and flower bulbs to professionals, horticulturists, market gardeners, and communities in france, rest of europe, the middle east, africa, and internationally. it also produces seeds and young horticultural plants. the company was founded in 1985 and is headquartered in colmar, france.

earnings per share

as for profitability, graines voltz has a trailing twelve months eps of €3.26.

pe ratio

graines voltz has a trailing twelve months price to earnings ratio of 16.4. meaning, the purchaser of the share is investing €16.4 for every euro of annual earnings.

more news about graines voltz (grvo.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com